Abstract
Neurology-led cognitive services play an important role in the diagnosis and management of dementia, particularly young onset and atypical dementias. Previous national audits have focused on psychiatry-led memory services. Here we present the first audit of neurology-led cognitive services across the UK. We present our findings covering a wide variety of services that offer biomarker supported diagnosis, with variable capacity for research and emerging therapies. This audit provides information to plan national priorities for neurology-led cognitive services.
Introduction
The first memory clinics were established in the UK in the early 1990s, beginning in academic neurology departments. Since then cognitive services have expanded across England, particularly following the 2009 national dementia strategy “Living Well With Dementia” [1], with parallel developments in the devolved nations. There have been previous audits of psychiatry-led Memory Assessment Services highlighting inequity in access to services and infrastructure across the country [2-4].
Neurology led cognitive services have tended to concentrate on people with young onset, rare, and genetic neurodegenerative disorders. They are based in acute hospital trusts, and potentially face different challenges and issues to psychiatry-led community-based services.
Research has been integrated into many neurology-led UK memory clinics from their beginning. Neurologists working in cognitive services in the UK have pioneered key cognitive instruments [5,6], neuroimaging [7], described neurodegenerative syndromes such as semantic dementia and variant Creuzfeldt-Jakob disease [8,9], led on diagnostic criteria such as Posterior Cortical Atrophy [10], and lead international cohorts of rare genetic dementias [11,12]. More recently, neurology-led services have developed clinical trials of novel treatments [13].
The field of neurodegeneration, and therefore the potential demands on cognitive services, is changing rapidly. Disease modifying treatments to slow the progression of Alzheimer’s disease are starting to enter clinical practice, although are yet to be approved for use in the NHS [14,15]. Novel PET, blood, and digital/artificial intelligence biomarkers are demonstrating promise for clinical practice.
Given these developments, it is timely to take stock of where neurology-led cognitive services stand in the UK. This will help to build for the future, and assess current capacity to roll out new treatments, expand research efforts including clinical trials, and evaluate new biomarkers.
Methods
We designed a survey for neurology-led cognitive services in the UK. Services self-identified as being eligible to participate. We requested that one person from each service complete the survey. In one case we received two responses and combined the two sets of answers.
Our starting point was the most recently completed (at the time) psychiatry-led memory services audit [3]. The survey consisted of two sections. The first section collated information about clinic staffing,
infrastructure and capacity. The second was an audit of activity over the previous 12 months. In addition to refining existing questions, we added additional questions relevant to neurology practice. These focused on capacity for infusion therapies, current and future research capacity including clinical trials, and current and future use of new technologies and biomarkers.
A total of 50 questions were uploaded to a website (dementiadata.com) for collection through a web-based form. Participants were asked to complete the audit of clinical activity between 1st January 2023 and 31st December 2023.
We distributed the survey through the Association of British Neurologists Cognitive Special Interest Group and personal contacts.
Results
Service infrastructure and capacity
We received completed responses from 20 NHS Trusts (Figure 1).

Service capacity
Staffing levels within each service are shown in Figure 2. This reveals large variation between services. A number of services rely on one or two consultants with less than full-time commitment to the cognitive service, accompanied by varying levels of part-time support staff. At the other end of the spectrum are two particularly large services (both in London) with a number of doctors, supported by a substantial multidisciplinary team. The median length for new appointments is 60 minutes (range 40 to 75 minutes). For follow-up appointments, the median appointment length is 30 minutes (range 15 to 30 minutes)
Postdiagnostic support
Postdiagnostic support is offered in 18 services, with 2 offering no post-diagnostic support. In those services offering support, 11 offer postdiagnostic support for all patients, and 3 provide support only for patients prescribed medication. The remaining 4 services provide post-diagnostic support depending on need, capacity, or whether they will be seen in other locally available services. A named contact for emotional support during the assessment period is available in 7 services. A named contact for emotional support following a diagnosis is available in 7 services.

Access to diagnostic biomarkers
All sites have basic blood tests, MRI scans as the primary imaging modality, CSF Alzheimer biomarkers, and genetic testing available. Neuropsychological assessment is available at 19 of 20 centres, FDG-PET at 15 centres, and SPECT at 8 centres.
Figure 3 shows that most services have access to FDG-PET as a standard service, with a small number having access to amyloid-PET imaging.

Non-dementia memory syndromes
We asked what diagnostic labels are used for people with attentional or working memory symptoms not caused by dementia, see Table 1. The term ‘functional memory disorder’ was the most commonly used label, but ‘attentional memory disorder’ is also widely used.

Research Involvement
There were 16 services involved in research.
In terms of drug studies specifically:
- 9 services run clinical trials at their institution
- 1 service does not currently run clinical trials, but plans to do so soon
- 6 services do not have capacity to run clinical trials
- 2 services are a Participant Information Centre (PIC) site for clinical trials run at other institutions
- 2 services are not involved in clinical trials, but refer others onward for clinical trial recruitment
In those sites running trials, there are a median number of 4 drug studies at each centre (range 1 to 20).
In terms of capacity for clinical trials, Figure 4 shows that almost all centres are engaged in a range of trial types, with slightly fewer (15) offering early phase Ib/II trials.

Future biomarker and technology
Two services use automated software to analyse brain imaging in selected cases to quantify volumetric changes using:
- Boundary Shift Integrals
- cNeuro software
No services use machine learning or artificial intelligence methods.
Infusion sites
There are 18 services with access to an infusion therapy, with 2 not certain if they have access. With the advent of treatments potentially requiring regular infusions, we asked about capacity for infusion therapies, (Figure 5). We found relatively low capacity to provide infusion therapies, with half of services able to offer 50 or fewer infusions. Even with additional funding, only 7 services thought they would be able to manage greater than 50 patients on infusion therapy.

circumstances, or where there were no financial constraints. Other constraints such as space and personnel may still be a limiting factor.
Audit of clinical work
Services were asked to provide information on their activity between 1st January 2023 and 31st December 2023. There were at least partial responses from 19 services.
Clinic activity
Figure 6 shows the types of clinical services provided, with a small majority (8 services) providing a general memory service only, and the others split between providing only subspecialist memory services, or a mixture of both general and subspecialist services.

The number or patients attending clinics varied greatly, see Figure 7, with a median of 400 patients (range 50-3000). When calculated per full-time equivalent (FTE) doctor in the clinic, the median number of patients per FTE was 600 (range 36-1350). Of these, 8 services are seeing more than 500 patients per year for each FTE consultant, with 5 of these seeing 1000 or more patients per FTE consultant. This suggests a large amount of work in these clinics is carried out by other staff (e.g. neuropsychologists, specialist nurses, resident doctors). In general terms, the higher number of patients per FTE consultant was found in the larger services, with the most doctors and patients.

Diagnostic patterns
Figure 8 demonstrates a wide variability between cognitive services in the patterns of diagnosis. In one service just less than half of the people seen have a diagnosis of Alzheimer’s disease, which is in line with audits of psychiatry-led services. However, the majority see fewer people with Alzheimer’s disease (as a proportion), in keeping with the traditional role of neurology-led services to see atypical neurodegenerative disorders.

Figure 9 shows a wide variety in the source of referrals to cognitive services. General practice and psychiatry are the main sources of referral, but the proportion varies significantly between services. Some services receive referrals almost solely from GPs, whereas others receive the bulk of their referrals from psychiatry, with most a mixture of the two. Only one service received the majority of their referrals from neurology, although for most services neurology referrals made up approximately 15-25% of all referrals.

Age
The age of patients reviewed in the cognitive services is shown in Figure 10. These figures are substantially younger than seen in old-age psychiatry led services, reflecting the demographic of people referred to neurology-led services. It is not possible to calculate a mean and range, as we asked about ranges rather than the individual age of patients seen.

Neuroimaging requests
Figure 11 shows that the overwhelming majority of scans requested were MRI scans. This contrasts with audits of mental health services where about two-thirds of scans are CT scans. Interestingly, sites reported requesting more non-FDG PET scans than FDG-PET, suggesting that those services with amyloid PET available are making use of it relatively frequently, despite it not being reimbursed by NHS England.

Discussion
We surveyed neurology led cognitive services across the UK. This is the first such audit, and adds to previous national audits focusing on psychiatry-led memory assessment services.
| Sign up for ACNR email updates – the latest articles in your inbox |
We found a group of clinics offering a specialised service to a large number of people with cognitive symptoms, complementing community-based psychiatry-led services. These services are variable across the county, ranging from small single-handed clinics to large multidisciplinary teams. The variability in capacity for research and trials is an area of concern. Neurology-led services have good access to biomarkers and will likely continue to evolve as newer blood-based and AI-based/digital biomarkers emerge. The readiness for novel treatments is variable, with some potential increased capacity possible.
We hope that our findings will support the development of larger scale multidisciplinary clinics, increased joint working with neighbourhood, mental health and care of the elderly teams, and the development of capacity for research, novel biomarkers and disease modifying treatments.
References
- Department of Health, Living well with dementia: A national dementia strategy, 2009.
- Cook L, Souris H, Isaacs J. The 2019 national memory service audit, Dementia Clinical Network, NHS
England, 2019. - Corrado O, Essel R, Fitch-Bunce C, Garling E, Hood C, Nicholls D, Quirk A, Swanson B. National Audit of Dementia Memory Assessment Services Spotlight Audit 2021, Royal College of Psychiatrists, London, 2022.
- Nicholls D, Quirk DA, Corrado DO, Swanson B, Hood C, Essel R, Chasse C, Davies R, Tulsiyani KJ, Olowu R. Royal College of Psychiatrists (2023/24) National Audit of Dementia Spotlight Audit in Memory Assessment Services national report, Royal College of Psychiatrist, 2024.
- Miosh E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke’s Cognitive Examination Revised (ACE-R): A brief cognitive test battery for dementia screening. International Journal of Geriatric Psychiatry. 2006 ;21:1078–1085. https://doi.org/10.1002/gps.1610.
- Brown J, Pengas G, Dawson K, Brown LA, Clatworthy P. Self administered cognitive screening test (TYM) for detection of Alzheimer’s disease: Cross sectional study. BMJ 338 (2009) b2030. https://doi.org/10.1136/bmj.b2030.
- Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer’s disease. The Lancet. 1996;348:94–97. https://doi.org/10.1016/S0140-6736(96)05228-2.
- Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic Dementia: Progressive Fluent Aphasia with Temporal Lobe Atrophy. Brain. 1992;115:1783–1806. https://doi.org/10.1093/brain/115.6.1783.
- Collinge J, Beck J, Campbell T, Estibeiro K, Will RG. Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease. The Lancet. 1996;348:56. https://doi.org/10.1016/S0140-6736(05)64378-4.
- Crutch SJ, Schott JM, Lehmann M, Primativo S, Rossor MN, Ryan NS, Shakespeare TJ, Suárez A, González, Yong KXX, Fox NC, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, Pijnenburg Y, Scheltens P, Dickerson BC, Vandenberghe R, Ahmed S, Butler C, Bak TH, Boeve BF, Graff-Radford J, Cappa SF, Ceccaldi M, de Souza LC, Dubois B, Felician O, Galasko D, Graff NR, Radford PR, Hof P, Krolak-Salmon P, Magnin PE, Mendez MF, Nestor PJ, Onyike CU, Pelak VS, Tang-Wai DF, Carrillo M. Consensus classification of posterior cortical atrophy, Alzheimer’s and Dementia. 2017;13:870–884. https://doi.org/10.1016/j.jalz.2017.01.014.
- Rohrer JD, Nicholas JM, Cash DM, Swieten JV, Dopper E, Jiskoot L, Minkelen RV, Rombouts SARB, Cardoso MJ, Clegg S, Espak M, Mead S, Thomas DL, Vita ED, Masellis M, Black SE, Freedman M, Keren R, Macintosh BJ, Rogaeva E, Tang-wai D, Tartaglia MC, F. Tagliavini RL Jr, Tiraboschi P, Redaelli V, Prioni S, Grisoli M , Borroni B, Padovani A, Galimberti D, Scarpini E, Arighi A, Thonberg H, Lilius L, Frisoni GB, Pievani M, Bocchetta M, Benussi L, Ghidoni R, Finger E, Sorbi S, Nacmias B, Lombardi G, Polito C, Warren JD, Ourselin S, Fox NC, Rossor MN. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative ( GENFI ) study : A cross-sectional analysis. Lancet Neurology 2015;14:253–262. https://doi.org/10.1016/S1474-4422(14)70324-2.
- Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. The Lancet Neurology 2009;8:791–801. https://doi.org/10.1016/S1474-4422(09)70170-X.
- Mummery CJ, Börjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, Jonsson M, Schneider A, Rinne JO, Ludolph AC, Bodenschatz R, Kordasiewicz H, Swayze EE, Fitzsimmons B, Mignon L, Moore KM, Yun C, Baumann T, Li D, Norris DA, Crean R, Graham DL, Huang E, Ratti E, Bennett CF, Junge C, Lane RM. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: A phase 1b, randomized, placebo-controlled trial, Nature Medicine. 2023;29:1437–1447. https://doi.org/10.1038/s41591-023-02326-3.
- van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer’s Disease, New England Journal of Medicine. 2022 https://doi.org/10.1056/NEJMoa2212948.
- Budd S, Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Z, Sandrock A. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease, The Journal of Prevention of Alzheimer’s Disease. (2022). https://doi.org/10.14283/jpad.2022.30.

